Kemicetina

Kemicetina Brand names, Kemicetina Analogs

Kemicetina Brand Names Mixture

No information avaliable

Kemicetina Chemical_Formula

C₁₁H₁₂Cl₂N₂O₅

Kemicetina RX_link

http://www.rxlist.com/cgi/generic3/chloramphenicol.htm

Kemicetina fda sheet

Kemicetina FDA

Kemicetina msds (material safety sheet)

Kemicetina MSDS

Kemicetina Synthesis Reference

No information avaliable

Kemicetina Molecular Weight

323.129 g/mol

Kemicetina Melting Point

150.5 ^oC

Kemicetina H₂O Solubility

2500 mg/L (at 25 °C)

Kemicetina State

Solid

Kemicetina LogP

1.476

Kemicetina Dosage Forms

Capsule; Drops; Liquid; Ointment; Powder; Solution; Suspension; Tablet

Kemicetina Indication

Used in treatment of cholera, as it destroys the vibrios and decreases the diarrhea. It is effective against tetracycline-resistant vibrios. It is also used in eye drops or ointment to treat bacterial conjunctivitis.

Kemicetina Pharmacology

Chloramphenicol is a broad-spectrum antibiotic that was derived from the bacterium Streptomyces venezuelae and is now produced synthetically. Chloramphenicol is effective against a wide variety of microorganisms, but due to serious side-effects (e.g., damage to the bone marrow, including aplastic anemia) in humans, it is usually reserved for the treatment of serious and life-threatening infections (e.g., typhoid fever). Chloramphenicol is bacteriostatic but may be bactericidal in high concentrations or when used against highly susceptible organisms. Chloramphenicol stops bacterial growth by binding to the bacterial ribosome (blocking peptidyl transferase) and inhibiting protein synthesis.

Kemicetina Absorption

Rapidly and completely absorbed from gastrointestinal tract following oral administration (bioavailability 80%). Well absorbed following intramuscular administration (bioavailability 70%). Intraocular and some systemic absorption also occurs after topical application to the eye.

Kemicetina side effects and Toxicity

Oral, mouse: LD₅₀ = 1500 mg/kg; Oral, rat: LD₅₀ = 2500 mg/kg. Toxic reactions including fatalities have occurred in the premature and newborn; the signs and symptoms associated with these reactions have been referred to as the gray syndrome. Symptoms include (in order of appearance) abdominal distension with or without emesis, progressive pallid cyanosis, vasomotor collapse frequently accompanied by irregular respiration, and death within a few hours of onset of these symptoms.

Kemicetina Patient Information